Bezitramide Stats & Data

Bezitramide has a very slow oral onset (lag ~0.5–1 h; peak ~2.5–3.5 h) and a long apparent elimination half‑life (~11–24 h), which strongly increases the risk that users will redose before the first dose peaks; multiple early overdoses have occurred with this pattern. Its parent drug and active metabolite (R‑4618, often called despropionyl‑bezitramide) are primarily handled via gastrointestinal hydrolysis and biliary excretion, with <0.3% of a dose renally excreted unchanged; effects can therefore be prolonged and variable across individuals. Combining any opioid with other CNS depressants (benzodiazepines, alcohol, gabapentinoids, Z‑drugs) markedly increases risk of respiratory depression and serious outcomes; this is well documented at a population level. In overdose, naloxone will reverse respiratory depression but its duration (roughly 1–2 hours) is shorter than bezitramide’s, so repeated dosing or an IV infusion and prolonged observation (6–12 h or longer) may be required to prevent renarcotization. Because of poor water solubility and oral‑only design, non‑oral routes (e.g., injection, insufflation) are not advisable and may be ineffective/dangerous. Bezitramide was withdrawn from the Dutch market following fatal overdoses reported in 2004; legacy 5 mg tablets (Burgodin) represent a very high dose for opioid‑naïve persons and should not be used as a reference for safe non‑medical dosing. Tolerance to euphoric and analgesic effects can build quickly with repeated use, but tolerance to respiratory depression is incomplete; returning to previous doses after a break is a major overdose risk. Some opioids (notably meperidine, methadone, tramadol) have serotonergic liability; while direct evidence for bezitramide is limited, extra caution with serotonergic drugs is prudent. Always measure doses precisely (milligram scale or volumetric dosing) given sub‑mg to low‑mg activity reported anecdotally. Keep naloxone available and ensure others know to call emergency services, place in recovery position, and monitor breathing if sedation deepens after an initial reversal.